Search Results - "HERTZ, CHRISTIN L."

Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes by Overgaard, Rune V., Hertz, Christin L., Ingwersen, Steen H., Navarria, Andrea, Drucker, Daniel J.

“…Glucagon-like peptide-1 receptor agonists (GLP-1RA) are used for the treatment of type 2 diabetes. Whether clinically important responses and adverse events…”
Get full text

Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial by Buse, John B, Bode, Bruce W, Mertens, Ann, Cho, Young Min, Christiansen, Erik, Hertz, Christin L, Nielsen, Morten A, Pieber, Thomas R

“…IntroductionThe PIONEER 7 trial demonstrated superior glycemic control and weight loss with once-daily oral semaglutide with flexible dose adjustment versus…”
Get full text

Personality in Adults Who Were Born Very Preterm by Hertz, Christin L, Mathiasen, René, Hansen, Bo M, Mortensen, Erik L, Greisen, Gorm

“…To investigate the personality in very preterm individuals (VPT; gestational age, GA, <32 weeks) at adult age in two cohorts born in 1974-76 and 1980-82,…”
Get full text

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes by Aroda, Vanita R, Rosenstock, Julio, Terauchi, Yasuo, Altuntas, Yuksel, Lalic, Nebojsa M, Morales Villegas, Enrique C, Jeppesen, Ole K, Christiansen, Erik, Hertz, Christin L, Haluzík, Martin

“…This trial compared the efficacy and safety of the first oral glucagon-like peptide 1 (GLP-1) receptor agonist, oral semaglutide, as monotherapy with placebo…”
Get full text

670-P: Time Spent in Glycemic Control after Initiating Treatment with Oral Semaglutide vs. Empagliflozin: An Exploratory Analysis of the PIONEER 2 Trial by ROSENSTOCK, JULIO, CARIOU, BERTRAND, CHRISTIANSEN, ERIK, HERTZ, CHRISTIN L., MONTANYA, EDUARD, NIELSEN, MORTEN ABILDLUND, KNOP, FILIP K.

“…A standard objective in the management of T2D is the achievement and maintenance of HbA1c targets, but the duration of time that patients spend within glycemic…”
Get full text

Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A population‐based observational retrospective cohort study by Khunti, Kamlesh, Hertz, Christin L., Husemoen, Lise Lotte N., Mocevic, Emina, Nordsborg, Rikke B., Piltoft, Johanne S., Bain, Stephen C.

“…Aims To characterise the cardiovascular risk of people with type 2 diabetes without established cardiovascular disease but with risk factors, relative to those…”
Get full text

932-P: Efficacy and Safety of Oral Semaglutide by Baseline Age in the PIONEER Clinical Trial Program by ARODA, VANITA R., BAUER, ROBERT, HERTZ, CHRISTIN L., MONTANYA, EDUARD, SØRRIG, RASMUS, WARREN, MARK L., CARIOU, BERTRAND

“…In an exploratory analysis of 7 global phase 3a trials (PIONEER 1-5, 7, and 8) we evaluated the effect of age at baseline on efficacy (<45, ≥45-<65, or ≥65…”
Get full text

964-P: Glycemic and Body Weight Responses to Oral Semaglutide in the PIONEER Trial Program by DUNGAN, KATHLEEN M., HERTZ, CHRISTIN L., MELLBIN, LINDA, NIELSEN, MORTEN ABILDLUND, SØRRIG, RASMUS, WOO, VINCENT C., VILSBØLL, TINA

“…The PIONEER phase 3 program investigated glycemic response and other efficacy endpoints in patients (pts) with type 2 diabetes randomized to the glucagon-like…”
Get full text

957-P: Efficacy of Oral Semaglutide According to Background Medication: An Exploratory Subgroup Analysis of the PIONEER Trial Program by BUSE, JOHN B., CROWLEY, MATTHEW, ERIKSSON, JAN W., GISLUM, METTE, HERTZ, CHRISTIN L., KAISER, MARCEL, NIELSEN, ANNE MOELLER, HALUZIK, MARTIN

“…The global PIONEER program investigated the efficacy and safety of the first oral glucagon-like peptide-1 receptor agonist, oral semaglutide. Across PIONEER…”
Get full text

A comparison of genetic findings in sudden cardiac death victims and cardiac patients: the importance of phenotypic classification by Hertz, Christin L, Ferrero-Miliani, Laura, Frank-Hansen, Rune, Morling, Niels, Bundgaard, Henning

“…Sudden cardiac death (SCD) is responsible for a large proportion of non-traumatic, sudden and unexpected deaths in young individuals. Sudden cardiac death is a…”
Get full text

Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses by Pratley, Richard E., Crowley, Matthew J., Gislum, Mette, Hertz, Christin L., Jensen, Thomas B., Khunti, Kamlesh, Mosenzon, Ofri, Buse, John B.

“…Introduction The efficacy and safety of oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist, were investigated in patients with type 2…”
Get full text

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial by Pieber, Thomas R, Bode, Bruce, Mertens, Ann, Cho, Young Min, Christiansen, Erik, Hertz, Christin L, Wallenstein, Signe O R, Buse, John B, Akın, S, Aladağ, N, Arif, A A, Aronne, L J, Aronoff, S, Ataoglu, E, Baik, S H, Bays, H, Beckett, P L, Berker, D, Bilz, S, Bode, B, Braun, E W, Buse, J B, Canani, L H S, Cho, Y M, Chung, C H, Colin, I, Condit, J, Cooper, J, Delgado, B, Eagerton, D C, El Ebrashy, I N, El Hefnawy, M H M F, Eliaschewitz, F G, Finneran, M P, Fischli, S, Fließer-Görzer, E, Geohas, J, Godbole, N A, Golay, A, Gorban de Lapertosa, S, Gross, J L, Gulseth, H L, Helland, F, Høivik, H O, Issa, C, Kang, E S, Keller, C, Khalil, S H A, Kim, N H, Kim, I J, Klaff, L J, Laimer, M, LaRocque, J C, Lederman, S N, Lee, K-W, Litchfield, W R, Manning, M B, Mertens, A, Morawski, E J, Murray, A V, Nicol, P R, O'Connor, T M, Oğuz, A, Ong, S, Özdemir, A, Palace, E M, Palchick, B A, Pereles-Ortiz, J, Pieber, T, Prager, R, Preumont, V, Riffer, E, Rista, L, Rudofsky, G, Sarı, R, Scheen, A, Schultes, B, Seo, J A, Shelbaya, S A, Sivalingam, K, Sorli, C H, Stäuble, S, Streja, D A, T'Sjoen, G, Tetiker, T, Van Gaal, L, Vercammen, C, Warren, M L, Weinstein, D L, Weiss, D, White, A, Winnie, M, Wium, C, Yavuz, D

“…Oral semaglutide is the first oral formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 diabetes. We aimed…”
Get full text

Effect and Safety of Oral Semaglutide Monotherapy in Type 2 Diabetes—PIONEER 1 Trial by ARODA, VANITA R., ROSENSTOCK, JULIO, TERAUCHI, YASUO, JEPPESEN, OLE, CHRISTIANSEN, ERIK, HERTZ, CHRISTIN L., HALUZIK, MARTIN

“…Oral semaglutide (sema), the first GLP-1 receptor agonist in a tablet formulation, is in late-stage development for the treatment of T2D. The effect and safety…”
Get full text

983-P: Effect and Safety of Flexible Dose Adjustment with Oral Semaglutide vs. Sitagliptin in Type 2 Diabetes: PIONEER 7 by BUSE, JOHN B., BODE, BRUCE W., CHO, YOUNG MIN, CHRISTIANSEN, ERIK, HERTZ, CHRISTIN L., MERTENS, ANN, WALLENSTEIN, SIGNE O., PIEBER, THOMAS R.

“…Oral semaglutide (sema) is the first oral GLP-1 receptor agonist (RA). Flexible dose adjustment of oral sema (3, 7, and 14 mg) once daily (N=253) was tested…”
Get full text

Abstract 34: Time spent in glycemic control after initiating treatment with oral semaglutide versus empagliflozin: An exploratory analysis of the PIONEER 2 trial by Prakash, Prashanth S, Rosenstock, Julio, Cariou, Bertrand, Christiansen, Erik, Hertz, Christin l, Montanya, Eduard, Nielsen, Morten Abildlund, Knop, Filip K

“…A standard objective in the management of T2D is the achievement and maintenance of HbA1C targets, but the duration of time that patients spend within glycemic…”
Get full text

Oral Semaglutide Reduces HbA.sub.1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses by Pratley, Richard E, Crowley, Matthew J, Gislum, Mette, Hertz, Christin L, Jensen, Thomas B, Khunti, Kamlesh, Mosenzon, Ofri

“…Introduction The efficacy and safety of oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist, were investigated in patients with type 2…”
Get full text

Abstract 15: Glycemic and body weight responses to oral semaglutide in the PIONEER trial program by Kumar, K B Sharan, Dungan, Kathleen M, Hertz, Christin L, Mellibin, Linda, Nielsen, Morten Abildlund, Sorrig, Rasmus, Woo, Vincent C, Vilsboll, Tina

“…Case: The PIONEER phase 3 program investigated glycemic response and other efficacy endpoints in patients (pts) with type 2 diabetes randomized to the…”
Get full text

Oral Semaglutide Reduces HbA 1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses by Pratley, Richard E, Crowley, Matthew J, Gislum, Mette, Hertz, Christin L, Jensen, Thomas B, Khunti, Kamlesh, Mosenzon, Ofri, Buse, John B

“…The efficacy and safety of oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist, were investigated in patients with type 2 diabetes (T2D)…”
Get full text